Carboplatin
Primary Peritoneal Serous Adenocarcinoma
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07504588CT.gov Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | — | Not Yet Recruiting | — | — | — |
NCT05276973CT.gov Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05415709CT.gov Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | — | Recruiting | — | — | — |
NCT02756130CT.gov Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | — | Withdrawn | — | — | — |
NCT02713386CT.gov Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT00989651CT.gov Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Peritoneal Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | National Cancer Institute (NCI) | P3 | BBB · 72 |
| Olaparib | NRG Oncology | P3 | BB |
| Letrozole | NRG Oncology | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P2/3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P2/3 | BB |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Ohio State University Comprehensive Cancer Center | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | B |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | B |
+36 more in the Primary Peritoneal Serous Adenocarcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Carboplatin in Primary Peritoneal Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/carboplatin-primary-peritoneal-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →